In the news | 1st Feb 2022
What's in Store for 2022? Our Experts Weigh in
Around this time last year, the first COVID-19 vaccines were authorized for emergency use by organizations such as the FDA, the EMA, the MHRA and many more internationally. A year before that, COVID-19 had not yet been declared a pandemic. It goes to show how much can change in this industry, as well as how important this sector is. With what we know – having adapted constantly since March 2020 and having also experienced uncertainty as new variants are discovered – predictions from industry experts for 2022 are important and illuminating.
Hear from experts, including Alberto Pascual, in this article, published in Drug Discovery World.
European Biomanufacturing Summit 2023
Come and join us at booth 130 in Amsterdam, to learn how an innovative tech transfer approach can revolutionize drug manufacturing in the pharmaceutical industry.
IDBS events roundup: Q1 highlights and Q2 events
IDBS associates had the opportunity to attend some events in Q1 and attendees were eager to see, hear and learn more about what’s happening in the industry.
How to improve time-to-value using GxP computer systems
Explore the benefits of GxP computer systems to improve time-to-value so that companies can speed up the development and manufacture of life-saving drugs.
New process definition capabilities in PIMS enhance quality assurance and validation for pharma manufacturers
IDBS reveals new process definition-handling capabilities in PIMS 5.0, which enhance quality assurance and validation for pharma manufacturers.